Overview

This trial is active, not recruiting.

Condition coronary artery disease
Treatment cormatrix extra cellular matrix (ecm)
Sponsor Inova Health Care Services
Collaborator CorMatrix Cardiovascular, Inc.
Start date January 2012
End date February 2013
Trial size 60 participants
Trial identifier NCT01535807, CorMatrix ECM Study

Summary

The objective of this study is to identify proteomic inflammatory biomarkers to determine if there are differences in the biomarkers in patients who are treated using the CorMatrix ECM implant to close the pericardium and the patients whose pericardium is left open (the current standard of care).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
The treatment "Cormatrix" group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique.
cormatrix extra cellular matrix (ecm) CorMatrix ECM, CorMatrix, ECM
Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique. No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care.
(No Intervention)
The control "No Intervention" group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care.

Primary Outcomes

Measure
Inflammatory biomarkers
time frame: Blood and Pericardial Fluid Baseline draw. Pericardial Fluid Post-Op Draw. Blood Post-Op draw Day 1 and Day 3.

Secondary Outcomes

Measure
Post Operative Atrial Fibrillation
time frame: Within 30 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Subject is ≥18 years of age - Subject must be selected as a candidate for isolated Coronary Artery Bypass Graft (CABG) procedure - Subject has a Left Ventricular Ejection Fraction (LVEF) of ≥30% - Subject is able and willing to provide written informed consent and HIPAA authorization - Subject has a life expectancy of at least one year Exclusion Criteria: - Subject is scheduled for other concomitant surgical procedures (carotid surgery included) - Subject has a known hypersensitivity to porcine material - Subject has a religious or cultural objection to the use of blood or porcine products - Subject is scheduled for Off Pump Coronary Artery Bypass procedures (OPCAB) - Subject has a history of diagnosed treated or un-treated pre-operative atrial fibrillation or any other type of cardiac arrhythmia - Subject has a history of anti-arrhythmic drug treatment in the past six (6) months - Subject has an implantable cardiac device (e.g., pacemakers, implantable cardioverter defibrillators) - Subject has a history of an accessory pathway disorder (e.g., Wolff-Parkinson-White syndrome) - Subject has a documented myocardial infarction (MI) within six (6) weeks prior to study enrollment - Subject needs emergent cardiac surgery (i.e., cardiogenic shock) - Subject requires intra-aortic balloon pump or intravenous inotropes - Subject has had an infection within six (6) weeks preceding surgery requiring antibiotic therapy - Subject is on pre-surgical immunosuppressive therapy (corticosteroids included) - Subject has chronic inflammatory disease (leukemia, lymphoma, arthritis, rheumatoid, lupus, Crohn's disease, ulcerative colitis, hepatitis C, HIV) - Subject has had therapeutic radiation to the pericardium, either prior to surgery or expected during the three (3) week period following surgery - There is an inability to approximate the graft and pericardium edge along the entire extent of the defect - Subject is incarcerated - Subject is participating in concomitant research studies of investigational products (e.g., Appendage closure devices, septal defect patches) - Subject is unable to provide informed consent

Additional Information

Official title CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without CorMatrix's Extra Cellular Matrix (ECM)
Principal investigator Niv Ad, MD
Description The pericardium's main function is to secrete proteins that ensure proper functioning within the pericardial space and to maintain pericardial pressure. Once dissected the pericardium is usually left open at the end of surgery due to the difficulty in realigning the edges and to avoid adverse effects cause by an inflammatory response. The body's inflammatory response is one of protection and healing of an injury. However many of the inflammatory biomarkers released can cause adverse outcomes after cardiac surgery, including: renal failure, myocardial infarction, atrial fibrillation, stroke and death. CorMatrix extra cellular matrix (ECM) Technology is a Food and Drug Administration (FDA) approved unique extra cellular implant material used for pericardial closure and reconstruction. Pericardial reconstruction using porcine intestinal ECM is a novel application. ECM combines the innate attributes of nature with the precision of science to help the heart heal itself. It is an acellular biomaterial that does not encapsulate when surgically implanted, but is gradually remodeled, leaving behind organized and healthy tissue. The body's tissue begins remodeling at the surgical site while the ECM maintains the needed tissue support. When implanted, the ECM acts as a scaffold into which the patient's cells migrate and integrate, stimulating the patient's natural wound-healing mechanisms. As the patient's cells become active, they lay down their own collagen, which matures over time to form strong and permanent tissue repair without leaving behind permanent foreign material. Because the ECM contains primarily collagen, the device is gradually replaced as the patient's tissue gradually turns over in a natural state of self-renewal. A retrospective study compared the incidence of post operative atrial fibrillation (POAF) in patients treated with the CorMatrix ECM for pericardial closure following isolated coronary artery bypass graft (CABG) versus patients not treated with the patch. The retrospective study comprised of 222 patients. 111 were treated with the CorMatrix ECM and the other 111 were not. Results showed POAF in 34 of 111 control patients but only 20 in 111 CorMatrix ECM treated patients, indicating a 54% decrease in the risk of POAF in the CorMatrix ECM treated patients. This study shows a statistically significant reduction in the risk of POAF in patients undergoing an isolated CABG with pericardial closure using the CorMatrix ECM. This is an unblinded, randomized study to identify proteomic inflammatory biomarkers to determine if there are differences in the biomarkers in patients who are treated using the CorMatrix ECM implant to close the pericardium and the patients whose pericardium is left open (the current standard of care). The study will be located at the Inova Heart and Vascular Institute (IHVI). The CorMatrix ECM will be implanted during the CABG surgical procedure in the IHVI cardiovascular operating rooms (CVOR). Sixty (60) patients who are routinely scheduled for a CABG will be recruited and randomly assigned to one of the two groups. There will be thirty (30) patients in each group. The control "No Intervention" group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care. The treatment "Cormatrix" group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique. Pericardial fluid and blood samples will be collected from all patients. Pericardial fluid and blood samples will undergo novel nanoparticle based biomarker discovery technology to harvest proteomic biomarkers at the George mason University. In addition, patients will have their cardiac rhythm continually assessed during their hospital stay and then at their follow up appointments with their surgeon and cardiologist to determine whether they developed POAF post discharge. Both genders, greater than eighteen (18) years of age, will be included in the research. There are no enrollment restrictions based upon race or ethnic origin and it is expected their inclusion will be representative of the population undergoing CABG at IHVI. Pregnant women are excluded from the study.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by Inova Health Care Services.